248 related articles for article (PubMed ID: 38322766)
1. Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology.
Quagliariello V; Passariello M; Bisceglia I; Paccone A; Inno A; Maurea C; Rapuano Lembo R; Manna L; Iovine M; Canale ML; Scherillo M; Ascierto PA; Gabrielli D; De Lorenzo C; Maurea N
Front Cardiovasc Med; 2024; 11():1232269. PubMed ID: 38322766
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways.
Quagliariello V; Passariello M; Di Mauro A; Cipullo C; Paccone A; Barbieri A; Palma G; Luciano A; Buccolo S; Bisceglia I; Canale ML; Gallucci G; Inno A; De Lorenzo C; Maurea N
Front Cardiovasc Med; 2022; 9():930797. PubMed ID: 36158826
[TBL] [Abstract][Full Text] [Related]
3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity of immune checkpoint inhibitors.
Varricchi G; Galdiero MR; Marone G; Criscuolo G; Triassi M; Bonaduce D; Marone G; Tocchetti CG
ESMO Open; 2017; 2(4):e000247. PubMed ID: 29104763
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
Kreidieh FY; Tawbi HA
Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
[TBL] [Abstract][Full Text] [Related]
8. Novel Combinations of Human Immunomodulatory mAbs Lacking Cardiotoxic Effects for Therapy of TNBC.
Vetrei C; Passariello M; Froechlich G; Rapuano Lembo R; Sasso E; Zambrano N; De Lorenzo C
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008285
[TBL] [Abstract][Full Text] [Related]
9. Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models.
Quagliariello V; Passariello M; Rea D; Barbieri A; Iovine M; Bonelli A; Caronna A; Botti G; De Lorenzo C; Maurea N
J Pers Med; 2020 Oct; 10(4):. PubMed ID: 33086484
[TBL] [Abstract][Full Text] [Related]
10. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
11. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
[No Abstract] [Full Text] [Related]
12. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.
Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; McGrath J; Sheppard AD; Hayes C; King R; Temperley H; MacLean M; Bulter C; Bhardwaj A; Moore J; Donohoe C; Ravi N; Conroy MJ; Reynolds JV; Lysaght J
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5377-5395. PubMed ID: 36445478
[TBL] [Abstract][Full Text] [Related]
13. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
[TBL] [Abstract][Full Text] [Related]
14. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).
Chae YK; Arya A; Iams W; Cruz MR; Chandra S; Choi J; Giles F
J Immunother Cancer; 2018 May; 6(1):39. PubMed ID: 29769148
[TBL] [Abstract][Full Text] [Related]
15. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
[TBL] [Abstract][Full Text] [Related]
16. Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer.
Dehno MN; Li Y; Weiher H; Schmidt-Wolf IGH
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349280
[TBL] [Abstract][Full Text] [Related]
17. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.
Vaddepally RK; Kharel P; Pandey R; Garje R; Chandra AB
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32245016
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab.
Graziani G; Lisi L; Tentori L; Navarra P
Exp Suppl; 2022; 113():295-350. PubMed ID: 35165868
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity.
Quagliariello V; Canale ML; Bisceglia I; Iovine M; Paccone A; Maurea C; Scherillo M; Merola A; Giordano V; Palma G; Luciano A; Bruzzese F; Zito Marino F; Montella M; Franco R; Berretta M; Gabrielli D; Gallucci G; Maurea N
Front Cardiovasc Med; 2024; 11():1289663. PubMed ID: 38818214
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer.
Rapoport BL; Shannon VR; Cooksley T; Johnson DB; Anderson L; Blidner AG; Tintinger GR; Anderson R
Front Pharmacol; 2021; 12():743582. PubMed ID: 34675810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]